Daily Alpha · Substack
· Post-Market Alpha · by Buzzberg Research
The public material pointed to vertical integration in AI hardware and a separate long-duration thesis in generative biology.
Themes on this desk
Custom inference silicon
SemiAnalysis highlighted OpenAI's announced Jalapeño inference chip and the coming benchmark test against Nvidia systems.
Generative biology
Outlier Capital framed AI drug discovery as a potential change in pharmaceutical development economics.
OpenAI announces Jalapeño inference ASIC
OpenAI has officially announced 'Jalapeño,' a custom-designed inference chip, following successful tapeout and internal lab validation.
Signals a strategic shift toward vertical integration in AI hardware to optimize inference costs and throughput, potentially challenging Nvidia's dominance in the inference market.
Watch Performance benchmarks and deployment timelines compared to Nvidia's Blackwell and Rubin architectures.
Source →AI drug discovery platforms identified as high-conviction investment
AI-driven drug discovery platforms are positioned as a high-conviction sector with the potential to fundamentally rewrite the economics of pharmaceutical development.
Suggests a shift in biotech valuation models toward companies leveraging generative biology to reduce R&D costs and timelines.
Watch Clinical trial success rates and partnership announcements for AI-native biotech firms.
Source →